Results of Clinical Trial for DAV132 Published in JID
announces the publication of full results of a clinical trial in humans for
DAV132, a product to protect the microbiota from disruption by antibiotics and
prevent C. difficile infections.
• The clinical study was the first worldwide demonstrating that an inventive colon-targeted adsorbent can prevent the disruption of the microbiome when antibiotics are prescribed.
• DAV132 is a first-in-class product to protect the microbiome during antibiotic treatments and prevent Clostridium difficile infections.